Several other equities research analysts also recently issued reports on TROV. Zacks Investment Research upgraded Trovagene from a sell rating to a hold rating in a report on Wednesday, July 13th. Piper Jaffray Cos. set a $4.00 price target on Trovagene and gave the stock a hold rating in a report on Friday, August 5th. Finally, Cantor Fitzgerald upgraded Trovagene from a hold rating to a buy rating and upped their price target for the stock from $5.00 to $7.00 in a report on Monday, August 8th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Trovagene presently has a consensus rating of Hold and a consensus target price of $6.54.
Trovagene (NASDAQ:TROV) opened at 4.40 on Thursday. The company’s market capitalization is $132.65 million. Trovagene has a 52 week low of $2.85 and a 52 week high of $7.18. The stock’s 50 day moving average is $4.76 and its 200 day moving average is $4.90.
Trovagene (NASDAQ:TROV) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by $0.03. Trovagene had a negative return on equity of 80.13% and a negative net margin of 8,495.00%. Analysts predict that Trovagene will post ($1.34) EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of TROV. First Heartland Consultants Inc. purchased a new position in shares of Trovagene during the second quarter worth approximately $103,000. Advisor Group Inc. purchased a new position in shares of Trovagene during the second quarter worth approximately $520,000. Rhumbline Advisers boosted its position in shares of Trovagene by 39.3% in the second quarter. Rhumbline Advisers now owns 39,171 shares of the company’s stock worth $177,000 after buying an additional 11,044 shares in the last quarter. BlackRock Investment Management LLC boosted its position in shares of Trovagene by 5.6% in the second quarter. BlackRock Investment Management LLC now owns 113,232 shares of the company’s stock worth $513,000 after buying an additional 5,964 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Trovagene by 3.2% in the second quarter. Vanguard Group Inc. now owns 979,014 shares of the company’s stock worth $4,435,000 after buying an additional 30,369 shares in the last quarter. 31.06% of the stock is currently owned by hedge funds and other institutional investors.
Trovagene Company Profile
Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.
Receive News & Ratings for Trovagene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trovagene Inc. and related companies with MarketBeat.com's FREE daily email newsletter.